First mRNA cancer drug developed by Moderna and Merck shows promise in reducing melanoma recurrence

Moderna and Merck & Co. have announced promising results from their collaboration on the first personalized mRNA cancer treatment drug, designed to reduce the recurrence of melanoma. This development marks a significant step in cancer therapy, moving beyond traditional treatments.

Taiwanese hematology-oncology physicians clarify that this innovative drug is not a preventative vaccine against infections. Instead, it is a highly personalized cancer treatment. The therapy involves analyzing each patient's specific tumor genetic mutations to identify potential targets for the immune system. Based on these findings, a tailored mRNA treatment is created for the individual.

“

This is not a vaccine for preventing infections, but a truly personalized cancer treatment.

Dr. Wu Jiao-en, Director of Hematology-Oncology at New Taipei City Tucheng Hospital, highlighted the drug's significance as the first product to achieve positive results in a Phase III clinical trial for cancer. He noted the evolution of cancer treatment from chemotherapy and targeted drugs to immunotherapy, ADC drugs, and cell therapies, emphasizing that a "cancer vaccine" like this is a novel advancement.

Due to the personalized nature of the treatment, it requires tissue samples, genetic analysis, and custom antigen design. This process means patients may need one to two months to receive the drug, and the cost is expected to be substantial. While the current focus is on melanoma due to its strong immune response and relatively fewer side effects, experts predict this success will spur further research and development of mRNA-based treatments for various other cancer types.

“

Therefore, Dr. Wu Jiao-en said, the importance of this drug lies in it being the first product to achieve success in a Phase III clinical trial. The research team will analyze the gene mutations of each patient's tumor to identify tumor neoantigens that can be recognized by the immune system, and then produce a dedicated mRNA treatment for this patient.